Financial Performance - Total assets decreased from $23,328,000 on December 31, 2022, to $12,950,000 on September 30, 2023, representing a decline of approximately 44.8%[23] - Total current assets fell from $10,051,000 to $3,090,000, a decrease of about 69.1%[23] - Collaboration revenue for the three months ended September 30, 2023, was $0, compared to $2,016,000 for the same period in 2022, indicating a 100% decline[26] - Total operating expenses decreased from $7,221,000 in Q3 2022 to $3,317,000 in Q3 2023, a reduction of approximately 54.8%[26] - The net loss for the three months ended September 30, 2023, was $5,256,000, compared to a net loss of $5,160,000 for the same period in 2022, reflecting a slight increase of 1.9%[26] - Basic and diluted loss per common share for Q3 2023 was $0.61, compared to $1.04 for Q3 2022, showing an improvement of approximately 41.3%[26] - The net loss for the nine months ended September 30, 2023, was $15,427,000, compared to a net loss of $20,978,000 for the same period in 2022, representing a 26% improvement[38] - Total revenue for the three months ended September 30, 2023, was $0.0 million, a decrease of $2.0 million, or 100%, from $2.0 million in the same period of 2022[155] - Total revenue for the nine months ended September 30, 2023, was $0.0 million, a decrease of $7.1 million, or 100%, from $7.1 million in the same period of 2022[163] Cash Flow and Liquidity - Cash, cash equivalents, and restricted cash at the end of the period were $2,122,000, down from $9,777,000 at the beginning of the period[40] - The company reported a net cash used in operating activities of $9,541,000 for the nine months ended September 30, 2023, compared to $28,382,000 for the same period in 2022, indicating a reduction of 66%[38] - The company has substantial doubt about its ability to continue as a going concern and will require substantial additional funding in the near term[139] - Cash and cash equivalents decreased from $0.9 million as of September 30, 2023, to approximately $0.2 million as of April 30, 2024[140] - Net cash used in operating activities was $9.5 million for the nine months ended September 30, 2023, a decrease of $18.8 million from $28.4 million in the same period of 2022, attributed to the suspension of R&D activities and reduced headcount[173] - The company reported net cash used in investing activities of $1.8 million for the nine months ended September 30, 2023, compared to net cash provided of $4.5 million in 2022, indicating a decrease of $6.3 million[175] - Net cash provided by financing activities was $3.7 million for the nine months ended September 30, 2023, primarily due to a Private Placement closed in February 2023[176] Strategic Alternatives and Risks - The company has substantial uncertainties regarding its ability to raise additional capital needed to fund operations and strategic alternatives[13] - The company is exploring strategic alternatives to maximize stockholder value, but faces risks related to identifying partners and securing funding[13] - The company is exploring transactions with potential partners in industries unrelated to its historical operations[43] - The company has halted all research and development activities and is not expected to generate significant value from its historical assets[138] - The company may seek bankruptcy protection if unable to raise capital, potentially resulting in little to no value for stockholders[141] - The company has received deficiency notices from Nasdaq regarding compliance with minimum bid price and stockholders' equity requirements[146] Management and Workforce - The company has experienced significant turnover in senior management, which poses continuity risks and may impair its ability to raise capital[20] - The company engaged in a significant reduction in force and suspended preclinical activities in September 2022, exploring strategic alternatives to maximize stockholder value[43] - The company reduced approximately 66% of its workforce as part of a strategic plan to decrease expenses and extend cash runway[142] Equity and Stockholder Information - The company reported a total stockholders' equity of $4,498,000 as of September 30, 2023, down from $14,922,000 at the end of 2022, a decrease of about 69.9%[23] - The balance of common stock increased from 4,965,901 shares at January 1, 2023, to 8,650,515 shares at September 30, 2023, reflecting an increase of approximately 74%[32] - The company has 8,650,515 shares of common stock issued and outstanding as of September 30, 2023, compared to 4,965,901 shares as of December 31, 2022[75] - CBI USA and its affiliates beneficially own 45% of the outstanding shares of Common Stock, with DGP expected to sell its remaining shares by June 30, 2024[79] Expenses and Cost Management - Equity-based compensation expenses for the nine months ended September 30, 2023, totaled $1,327,000, an increase from $1,141,000 in the prior year[38] - General and administrative expense for the nine months ended September 30, 2023, was $11.2 million, an increase of $2.4 million, or 27%, from $8.8 million for the same period in 2022[165] - The company has engaged in significant cost reductions, but further cost-cutting measures are limited, necessitating substantial additional financing in the near term[51] Asset Management - The company recognized a loss of $920 from the sale of scientific equipment during the nine months ended September 30, 2023[62] - The company impaired the entire $2 million amount of convertible securities, recognizing them at a fair value of $0 as of September 30, 2023[161] - The total financial assets measured at fair value as of September 30, 2023 were $659,000, down from $1,612,000 at the end of 2022[118] Compliance and Reporting - The company received a delinquency notification for not filing its third quarter Form 10-Q by the deadline, which is expected to be cured by the filing[154] - The company has irrevocably elected not to take advantage of the extended transition period under the JOBS Act, committing to adopt new accounting standards as required for public companies[181]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________________________________ FORM 10-Q ______________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39011 _____________________________________ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________________________________ FORM 10-Q ______________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39011 ____________________________________ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39011 ______________________________________ EXICURE, INC. (Exact name of regis ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________________________________ FORM 10-Q ______________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39011 ________________________________ ...

exicure® Pursuing Next Generation Nucleic Acid Therapies NASDAQ Ticker: XCUR August 2022 Cautionary Note Regarding Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "expect," "plan," "may," "will," "continue," and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All sta ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-Q ______________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39011 ______________________________________ EXICURE, INC. (Exact name of registrant as specified in its ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________________________________ FORM 10-Q ______________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39011 ____________________________________ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39011 ______________________________________ EXICURE, INC. (Exact name of regis ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________________________________ FORM 10-Q ______________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39011 ________________________________ ...